Figure/Table Caption List
Figure 1A.
Clinical courses of 19 cases with placental removal within 24 hours
after delivery
The numbers in “Size and blood flow of RPOC” indicate the size of RPOC
(mm).
The numbers in “After” and “Disappearance of RPOC” indicate the
duration from delivery to the onset of the events (days).
RPOC, retained products of conception
Figure 1B.
Clinical courses of 22 cases with conservative management.
The number in “Size and blood flow of RPOC” indicate the RPOC size
(mm).
The number in “Events” and “Disappearance of RPOC” indicate the
duration from delivery to the onset of event (days).
RPOC, retained products of conception
Figure 2.
The cumulative incidence rate of events in RPOC cases with conservative
management
The horizontal and vertical axes represent the duration from delivery to
the onset of the events (days) and the incidence rate (%),
respectively.
Cumulative incidence rates of heavy bleeding (A), blood transfusion (B),
UAE (C), and infection (D) in 22 cases with conservative management of
RPOC.
Cumulative incidence rates of heavy bleeding (E), blood transfusion (F),
UAE (G), and infection (H) in 16 cases without placental extraction
trial during conservative management, excluding five cases with
placental traction and one with D&C
RPOC, retained products of conception; UAE, uterine artery embolization;
D&C, dilatation and curettage
Figure 3.
The cumulative rate of placental resolution in RPOC cases with
conservative management
The horizontal and vertical axes indicate the duration from delivery to
resolution (days) and the cumulative incidence rate (%), respectively.
Arrows and arrow head indicate the timing of MROP and TCR, respectively.
RPOC, retained products of conception; MROP, manual removal of the
placenta; TCR, transcervical resection
Figure 4.
Serial changes in serum hCG
The horizontal and vertical axes indicate the duration from delivery to
the measurement date (days) and the serum hCG level (IU/L),
respectively.
(A)(B) RPOC cases delivered after 34 weeks of gestation
(A) Cases without UAE.
(B) Cases with UAE. Arrows show the date on which UAE was performed.
(C)(D) RPOC cases delivered at less than 20 weeks of gestation and did
not undergo UAE
(C) Cases with serum hCG half-life of less than 10 days
(D) Cases with serum hCG half-life of more than10 days
RPOC, retained products of conception; UAE, uterine artery embolization;
hCG, human chorionic gonadotropin
Figure S1.
Representative images of RPOC cases with conservative management
(A) Case 23: Contrast-enhanced CT with heavy bleeding showed strongly
contrast-enhanced RPOC in the arterial phase (postpartum day10). Arrows
show RPOC.
(B)-(F) case 37: Serial changes in contrast-enhanced MRI during
conservative management
(B) Sagittal T2WI showed an RPOC in the uterus. The RPOC size was 72 x
42 x 49 mm (postpartum day 3).
(C) Sagittal contrast T1WI demonstrated strongly contrasted RPOC
(postpartum day 3).
(D) Sagittal T2WI showed RPOC in the uterus, whose size became smaller.
The RPOC size was 22 x 17 x 15 mm (postpartum day 22).
(E) Sagittal contrast T1WI still demonstrated strongly contrasted RPOC
(postpartum day 22).
(F) MRI did not detect RPOC (postpartum day 64). Ultrasound showed RPOC
of 8 mm on postpartum day 87. On postpartum day 102, hysteroscopy showed
that the RPOC was 10 mm, and on postpartum day 201, it was finally
confirmed that the RPOC had disappeared.
CT, computed tomography; RPOC, retained products of conception; MRI,
magnetic resonance imaging; T2WI, T2-weighted imaging
Table S1.
Univariate analysis between RPOC with heavy bleeding and light bleeding
during conservative management
RPOC, retained products of conception
References
1. Tunçalp O, Souza JP, Gülmezoglu M: New WHO recommendations on
prevention and
treatment of postpartum hemorrhage. Int J Gynaecol Obstet 2013,
123:254-256.
2. Weissbach T, Haikin-Herzberger E, Bacci-Hugger K, Shechter-Maor G,
Fejgin M,
Biron-Shental T: Immediate postpartum ultrasound evaluation for
suspected retained placental tissue in patients undergoing manual
removal of placenta. Eur J Obstet Gynecol Reprod Biol 2015, 192:37-40.
3. Hoveyda F, MacKenzie IZ: Secondary postpartum haemorrhage: incidence,
morbidity
and current management. Bjog 2001, 108:927-930.
4. Urner F, Zimmermann R, Krafft A: Manual removal of the placenta after
vaginal
delivery: an unsolved problem in obstetrics. J Pregnancy 2014,
2014:274651.
5. Anteby M, Many A, Ashwal E, Yogev Y, Shinar S. Risk factors and
complications of
manual placental removal after vaginal delivery - how common are
additional invasive
procedures? J Matern Fetal Neonatal Med. 2019, 32:384-388.
6. Takahashi H, Ohhashi M, Baba Y, Nagayama S, Ogoyama M, Horie K, et
al.:
Conservative management of retained products of conception in the normal
placental position: A retrospective observational study. Eur J Obstet
Gynecol Reprod Biol 2019, 240:87-92.
7. Wada Y, Takahashi H, Suzuki H, Ohashi M, Ogoyama M, Nagayama S, et
al.:
Expectant management of retained products of conception following
abortion: A retrospective cohort study. Eur J Obstet Gynecol Reprod Biol
2021, 260:1-5.
8. Kobayashi M, Nakagawa S, Kawanishi Y, Masuda T, Maenaka T, Toda A, et
al.: The
RPOC long axis is a simple indicator for predicting the need of invasive
strategies for secondary postpartum hemorrhage in either post-abortion
or post-partum women: a retrospective case control study. BMC Pregnancy
Childbirth 2021, 21:653.
9. Sentilhes L, Ambroselli C, Kayem G, Provansal M, Fernandez H,
Perrotin F et al:
Maternal outcome after conservative treatment of placenta accreta.
Obstet Gynecol 2010, 115:526-534.
10. Foreste V, Gallo A, Manzi A, Riccardi C, Carugno J, Sardo ADS.
Hysteroscopy and Retained Products of Conception: An Update. Gynecol
Minim Invasive Ther. 2021, :203-209.
11. Vitale SG, Parry JP, Carugno J, Cholkeri-Singh A, Della Corte L,
Cianci S et al. Surgical and Reproductive Outcomes after Hysteroscopic
Removal of Retained Products of Conception: A Systematic Review and
Meta-analysis. J Minim Invasive Gynecol. 2021, 28:204-217.
12. Pather S, Ford M, Reid R, Sykes P. Postpartum curettage: an audit of
200 cases. Aust N Z J Obstet Gynaecol. 2005, 45:368-71.
13. Imai S, Kondoh E, Kawasaki K, Mogami H, Ueda A, Umeoka S et al. :
Placental blood flow disappears coincident with a fall in human
chorionic gonadotropin to undetectable levels in conservative management
of placenta accreta. Eur J Obstet Gynecol Reprod Biol 2014, 180:199-201.
14. Miyakoshi K, Otani T, Kondoh E, Makino S, Tanaka M, Takeda S:
Retrospective
multicenter study of leaving the placenta in situ for patients with
placenta previa on a cesarean scar. Int J Gynaecol Obstet 2018,
140:345-351.
15. Kamaya A, Krishnarao PM, Nayak N, Jeffrey RB, Maturen KE: Clinical
and imaging
predictors of management in retained products of conception. Abdom
Radiol (NY) 2016, 41:2429-2434.
16. Hooker AB, Aydin H, Brölmann HA, Huirne JA: Long-term complications
and reproductive outcome after the management of retained products of
conception: a systematic review. Fertil Steril 2016,
105:156-164.e151-152.
17. Fujita K, Ushida T, Imai K, Nakano-Kobayashi T, Iitani Y, Matsuo S,
et al.
: Manual removal of the placenta and postpartum hemorrhage: A
multicenter retrospective study. J Obstet Gynaecol Res 2021,
47:3867-3874.
18. Ikeda A, Kondoh E, Chigusa Y, Mogami H, Kameyama Nakao K, et al.
Novel subtype of atonic postpartum hemorrhage: dynamic computed
tomography evaluation of bleeding characteristics and the uterine
cavity. J Matern Fetal Neonatal Med. 2020, 33:3286-3292.
19. Furukawa S, Fujisaki M, Maki Y, Oohashi M, Doi K, Sameshima H.
Manual removal of placenta in women having unpredictable adherent
placenta. J Obstet Gynaecol Res. 2019, 45:141-147.
20. Creasy & Resnik’s Maternal-FETAL MEDICINE Principles and Practice
8th EDITION
21. Akiba N, Iriyama T, Nakayama T, Seyama T, Sayama S, Kumasawa K, et
al.
: Ultrasonographic vascularity assessment for predicting future severe
hemorrhage in retained products of conception after second-trimester
abortion. J Matern Fetal Neonatal Med 2021, 34:562-568.
22. Shitanaka S, Chigusa Y, Kawahara S, Kawasaki K, Mogami H, Mandai M,
et al.:
Conservative management for retained products of conception after less
than 22 weeks of gestation. J Obstet Gynaecol Res 2020, 46:1982-1987.
23. Grewal K, Al-Memar M, Fourie H, Stalder C, Timmerman D, Bourne T:
Natural
history of pregnancy-related enhanced myometrial vascularity following
miscarriage. Ultrasound Obstet Gynecol 2020, 55:676-682.
24. Midgley AR Jr, Jaffe RB. Regulation of human gonadotropins. II.
Disappearance of human chorionic gonadotropin following delivery. J Clin
Endocrinol Metab. 1968, 28:1712-8.
25. Matsumura N, Inoue T, Fukuoka M, Sagawa N, Fujii S. Changes in the
serum levels of human chorionic gonadotropin and the pulsatility index
of uterine arteries during conservative management of retained adherent
placenta. J Obstet Gynaecol Res. 2000, 26:81-7.
26. Fernandez H, Bourget P, Ville Y, Lelaidier C, Frydman R. Treatment
of unruptured tubal pregnancy with methotrexate: pharmacokinetic
analysis of local versus intramuscular administration. Fertil Steril.
1994, 62:943-7.
27. Ozeren M, Bilekli C, Aydemir V, Bozkaya H. Methotrexate and
misoprostol used alone or in combination for early abortion.
Contraception. 1999, 59:389-94.